Dosing and uses of Oxistat (oxiconazole)
Adult dosage forms and strengths
cream/lotion
- 1%
Fungal Infections
Apply qDay-BID to affected & surrounding area
Tinea pedis: x4 weeks
Tinea cruris & corporis: x2 weeks
Pediatric dosage forms and strengths
cream/lotion
- 1%
Fungal Infections
Apply qDay-BID to affected & surrounding area
These infections rarely occur in <12 years old
Oxistat (oxiconazole) adverse (side) effects
1-10%
Pruritus (1-2%)
Burning (1-2%)
<1%
Irritation
Stinging
Erythema
Rash
Folliculitis
Papules
Nodules
Maceration
Fissuring
Warnings
Contraindications
Hypersensitivity
Not for ophthalmic or intravaginal use
Pregnancy and lactation
Pregnancy category: B
Lactation: distributed into milk; use with caution in nursing women
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Oxistat (oxiconazole)
Absorption: minimaL
Excretion: urine (0.3%) within 5 days
Enzymes inhibited: hepatic CYP3A4
Mechanism of action
Fungistatic in action but may be fungicidal in high concentrations or against very susceptible organisms
Presumably exerts its antifungal activity by altering cellular membranes, resulting in increased membrane permeability, secondary metabolic effects, and growth inhibition
Appears that the antifungal activity of the drug results from interference with ergosterol synthesis, probably via inhibition of C-14 methylation of sterol intermediates (e.g., lanosterol)
